Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

10.6K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
10.6K
Ligand Binding Sites02:40

Ligand Binding Sites

11.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
11.8K
Ligand Binding Sites02:40

Ligand Binding Sites

6.0K
6.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymmetric Total Synthesis of C2-OH Lycopodium Alkaloids (-)-Palhinine B, (-)-Palhinine C, and (+)-Palhinine B Enabled by Stereocontrolled Diels-Alder Strategy.

Organic letters·2026
Same author

Global burden-integrated analysis of osteoarthritis research-to-translation dynamics, 1999-2023.

PloS one·2026
Same author

Cheminformatics analysis, machine learning-based QSAR model building and virtual screening: identification of dual ROCK1 and TGFBR1 inhibitors for the treatment of cancer metastasis.

Journal of molecular graphics & modelling·2026
Same author

Distinct temporal patterns of acute intermittent hypoxia differentially affect sleep, autonomic regulation, and cognition in normotensive and hypertensive rats.

Sleep medicine·2026
Same author

Zolpidem use and the risk of arrhythmia: A nationwide population-based cohort study in Taiwan.

Journal of the Chinese Medical Association : JCMA·2026
Same author

Differential cardiovascular and autonomic responses to structurally distinct intermittent hypoxia paradigms in rats.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Related Experiment Video

Updated: Apr 27, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

9.8K

Ligand efficiency based approach for efficient virtual screening of compound libraries.

Yi-Yu Ke1, Mohane Selvaraj Coumar2, Hui-Yi Shiao1

  • 1Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC.

European Journal of Medicinal Chemistry
|June 25, 2014
PubMed
Summary
This summary is machine-generated.

We developed a new virtual screening method using fit quality (FQ) to find aurora kinase A inhibitors. This approach identified novel inhibitors with improved efficiency and hit rates compared to traditional methods.

Keywords:
Aurora kinase inhibitorFit qualityLigand efficiencyPharmacophore modelVirtual screening

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

6.4K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

287

Related Experiment Videos

Last Updated: Apr 27, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

9.8K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

6.4K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

287

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Virtual screening (VS) is crucial for identifying novel drug candidates.
  • Ligand efficiency (LE) based methods offer improved accuracy in VS.
  • Aurora kinase A is a key target in cancer therapy.

Purpose of the Study:

  • To introduce and validate a novel VS protocol using fit quality (FQ), a ligand efficiency-based measure.
  • To identify novel inhibitors of aurora kinase A using the developed VS protocol.
  • To assess the efficiency and hit rate improvement offered by the FQ-based VS method.

Main Methods:

  • Developed a pharmacophore (PH) model from known aurora kinase inhibitors.
  • Screened a 125,000-compound library using the PH model.
  • Derived a weight-dependent LE function (LE_Scale) and calculated fit quality (FQ = LE/LE_Scale) scores.
  • Reranked compounds using FQ scores and performed biochemical assays on top candidates.

Main Results:

  • Identified 7 novel aurora kinase A inhibitors, including compound 5 (IC50 = 1.29 μM).
  • Compound 5 demonstrated selectivity for aurora kinase A and B over 31 other kinases.
  • The FQ-based VS protocol significantly improved the enrichment factor (EF = 828) compared to PH-based screening (EF = 237).

Conclusions:

  • The FQ score enhances VS by improving hit identification and enrichment.
  • The developed LE-based VS protocol is efficient for discovering novel kinase inhibitors.
  • This method holds potential for application to other therapeutic targets.